Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT Combined With Toripalimab and GP Chemotherapy for Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT07325539Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Jan 2026; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07325539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07325539.